Nuo Therapeutics, Inc.
AURX
$1.52
-$0.02-1.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 106.53% | 124.37% | 140.45% | 252.74% | 350.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.53% | 124.37% | 140.45% | 252.74% | 350.98% |
| Cost of Revenue | 124.41% | 140.13% | 164.68% | 321.36% | 461.82% |
| Gross Profit | 101.67% | 120.21% | 134.32% | 238.47% | 328.16% |
| SG&A Expenses | 2.67% | -3.58% | -12.34% | -8.66% | -4.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.00% | 1.22% | -7.99% | -4.41% | -0.60% |
| Operating Income | 17.49% | 22.43% | 28.70% | 25.23% | 17.29% |
| Income Before Tax | 21.93% | 26.73% | 28.68% | 25.20% | 17.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.93% | 26.73% | 28.68% | 25.20% | 17.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.93% | 26.73% | 28.68% | 25.20% | 17.19% |
| EBIT | 17.49% | 22.43% | 28.70% | 25.23% | 17.29% |
| EBITDA | 18.23% | 22.78% | 28.85% | 25.37% | 17.47% |
| EPS Basic | 27.89% | 32.05% | 32.49% | 28.09% | 20.05% |
| Normalized Basic EPS | 23.48% | 28.03% | 32.24% | 27.96% | 20.18% |
| EPS Diluted | 27.89% | 32.05% | 32.49% | 28.09% | 20.05% |
| Normalized Diluted EPS | 23.48% | 28.03% | 32.24% | 27.96% | 20.18% |
| Average Basic Shares Outstanding | 7.91% | 7.95% | 5.68% | 4.24% | 3.78% |
| Average Diluted Shares Outstanding | 7.91% | 7.95% | 5.68% | 4.24% | 3.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |